Healthcare Payors Agent Orchestration Build Vs Buy | Moring
For healthcare payors the orchestration build-versus-buy question splits into layers: most agents already arrive from vendor platforms, while the orchestration and governance layer that coordinates them increasingly looks like core infrastructure worth owning. Market data shows vendor agent spend roughly tripling in 2025, and the deciding factors are PHI data paths, identity, evidence, and whether bought components can be governed end to end.
Short answer
For healthcare payors the orchestration build-versus-buy question splits into layers: most agents already arrive from vendor platforms, while the orchestration and governance layer that coordinates them increasingly looks like core infrastructure worth owning. Market data shows vendor agent spend roughly tripling in 2025, and the deciding factors are PHI data paths, identity, evidence, and whether bought components can be governed end to end.
How it works
The build-versus-buy question for payor orchestration is really two questions, because the agent layer and the orchestration layer have different economics. On the agent layer, the market has already answered: analysis of enterprise automation reports that 61 percent of organizations use AI-vendor tools such as agent builders and agent SDKs to put AI into their workflows, making vendor platforms the single most common source of agents, most of them not built in-house. Each works well inside its own ecosystem, coordinates poorly with the others, and answers to no common governance model, which is precisely the problem the orchestration layer exists to solve.
The market context for healthcare is expanding quickly. Venture tracking of healthcare AI spending counted roughly 1.4 billion dollars in 2025, nearly triple the prior year, led by ambient documentation, followed by coding and billing, with prior authorization growing about tenfold. EHR incumbents are building agents natively, with one dominant vendor reporting that the large majority of its customers use its AI features and offering factories for health systems to build their own agents. A payor's build-versus-buy decision therefore starts from a crowded vendor field rather than a green field.
The build case concentrates on the boundaries vendors handle poorly. Practitioner guidance for healthcare agent builders identifies the questions that decide security reviews: who the agent acts as, where protected health information goes, and whether both can be proven. The business associate agreement chain has known gaps at the tool layer, with major model providers excluding many third-party integrations and live web features from coverage, so tool calls carrying PHI must run through covered infrastructure or inside the payor's own boundary. Identity is the second boundary: service accounts demo well and fail audit questions, and per-user delegation designed from day one avoids a later rewrite.
The buy case concentrates on speed and coverage. Building orchestration in-house means owning state management, handoff semantics, policy enforcement, retry and compensation logic, and the evidence pipeline, an investment that competes with the payor's other platform priorities and must be maintained as agent frameworks evolve. Buying the orchestration core while owning policy and integration lets a payor get identity enforcement, approval gates, cap enforcement, and logging from a platform whose full-time job is keeping pace with framework changes, provided the platform can run inside or adjacent to the payor's boundary and produce the records the payor needs.
The governance requirement is the tiebreaker most payors should weight heaviest, because it is where bought components most often disappoint. Whatever is bought must expose per-agent identity, policy checks at every hop, approval gates, cap enforcement, and exportable evidence, and the vendor must accept model change notification and audit obligations in contract. An orchestration platform that cannot meet those terms is not a governance layer; it is another ungoverned agent. The EU AI Act's expectations for in-scope systems flow to the deployer regardless of who built the software, so the payor cannot outsource accountability, only capability.
A hybrid landing fits most payors: buy agent capabilities and, where suitable, the orchestration platform's plumbing, while owning the policy layer, the identity model, the PHI data path, and the evidence standards. The decision test to apply to any component is whether the payor can govern it end to end and prove it in a security review; capability that cannot be governed is not a shortcut but a deferred liability.
Exit and portability deserve a place in the build-versus-buy analysis, because orchestration choices compound over time. A payor adopting a platform should secure contractual portability for the assets that matter: workflow definitions, evidence records, configuration, and the case history the orchestration layer accumulates, since switching costs grow with every dependent workflow. The build option's hidden advantage is optionality, an in-house layer can be replaced incrementally, while a platform commitment concentrates switching risk at a single decision point; the buy option's hidden advantage is that someone else carries the framework churn. Both options should be stress-tested against a vendor failure scenario: if the platform or the vendor-supplied agents stopped tomorrow, what runs the prior authorization and claims workflows, and how long is the fallback window. Payors should also revisit the decision on a defined cycle, typically annually, because the market is moving quickly and last year's build case may be this year's buy case, or the reverse. A decision framework that includes exit conditions prevents both lock-in drift and rebuild churn.
Frequently asked questions
Should a healthcare payor build or buy its AI agent orchestration layer?
Most payors should buy the orchestration plumbing and own the policy layer: identity, scope rules, approval gates, PHI data paths, and evidence standards. Building the full layer consumes scarce platform capacity and must track evolving agent frameworks, while buying without governance terms imports an ungoverned agent. Whichever way the payor leans, the decisive test is whether each component can be governed end to end and proven in a security review.
What PHI considerations drive the build-versus-buy decision?
Two boundaries matter most: the business associate agreement chain, which has gaps at the tool layer since major providers exclude many third-party integrations and live web features, and identity, where shared service accounts fail audit and minimum-necessary questions. Tool calls carrying PHI need covered infrastructure or the payor's own boundary, and per-user delegation should be designed from the start. A bought platform must support a written PHI data path and metadata-only logging options.
How much is the healthcare payor AI agent market growing?
Venture tracking counted roughly 1.4 billion dollars of healthcare AI spending in 2025, nearly triple the prior year, with ambient documentation leading, coding and billing next, and prior authorization growing about tenfold. EHR incumbents are also embedding agents natively, with one dominant vendor reporting the large majority of its customers using its AI features. This growth means payors choose among many vendor options rather than building everything, but it also raises the governance stakes for agent sprawl.
What obligations does a payor retain when it buys orchestration components?
Deployer obligations under the EU AI Act for in-scope systems, including documentation, human oversight, and logging, remain with the payor regardless of who built the software. Contracts should secure model change notification, audit rights, and evidence delivery from vendors, but they transfer capability rather than accountability. A payor should therefore verify at selection time that any bought component can produce the records the payor itself must be able to produce.